IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9181182 B1

PDFFull Text
Date of Patent:
Nov. 10, 2015

Filed:

Oct. 16, 2009

S1p receptors modulators

Applicants:

Damian W. Grobelny, Watsonia North, AU;

Gurmit S. Gill, Craigieburn, AU;

Inventors:

Damian W. Grobelny, Watsonia North, AU;

Gurmit S. Gill, Craigieburn, AU;

Assignee:

Akaal Pharma PTY LTD, Bundoora, AU;

Attorneys:

Cooley LLP

Heidi A. Erlacher

Lian Ouyang

Primary Examiner:

Barbara P Badio

Assistant Examiner:

Sara E Townsley

Int. Cl.
CPC ...
A61K 31/136 (2006.01); C07D 209/44 (2006.01); C07D 215/06 (2006.01); C07D 209/08 (2006.01); C07C 215/18 (2006.01); C07C 217/72 (2006.01); C07C 225/16 (2006.01); C07C 311/16 (2006.01); C07D 209/12 (2006.01); C07D 209/38 (2006.01); C07D 215/20 (2006.01); C07D 217/04 (2006.01); C07D 223/16 (2006.01); C07D 405/12 (2006.01); C07D 413/10 (2006.01); C07D 413/14 (2006.01);
U.S. Cl.
CPC ...
C07D 209/08 (2013.01); C07C 215/18 (2013.01); C07C 217/72 (2013.01); C07C 225/16 (2013.01); C07C 311/16 (2013.01); C07D 209/12 (2013.01); C07D 209/38 (2013.01); C07D 209/44 (2013.01); C07D 215/06 (2013.01); C07D 215/20 (2013.01); C07D 217/04 (2013.01); C07D 223/16 (2013.01); C07D 405/12 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01); C07C 2103/70 (2013.01); C07C 2103/74 (2013.01);
Abstract

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

Find Patent Forward Citations

Loading…